Glucose Health, Inc. reported a $60,000 equity offering under Rule 506(b), with $0 remaining to be sold. The notice lists October 5, 2026 as the first-sale date. It says the amount sold represents an accrued unpaid obligation for services, satisfied by issuing restricted shares to a recipient. A separate use-of-proceeds clarification describes restricted shares issued to an entity owned by an executive officer to satisfy an accrued services obligation.
Glucose Health, Inc. (GLUC) reported an exempt equity offering under Rule 506(b), with a total amount sold of $172,500 USD and $0 USD remaining to be sold. The $172,500 USD represents the value of additional restricted shares issued to a recipient for services rendered to the company. The first sale occurred September 22, 2026, and finders' fees were $0 USD.
Glucose Health, Inc. reported a Rule 506(b) exempt equity offering with $30,000 sold and $0 remaining. The $30,000 represents the value of restricted stock issued to a recipient for services rendered to the issuer. The first sale date was June 3, 2026.
Glucose Health, Inc. reported a Rule 506(b) exempt equity offering with $12,000 sold, representing the value of restricted shares issued for services; $0 remained to be sold. The first sale occurred August 7, 2026. The notice also identifies restricted stock issued to an entity owned by a director for services rendered to the issuer.
Glucose Health, Inc. (GLUC) filed a Form D to report a new exempt private offering of equity securities under Rule 506(b) of Regulation D. The company identifies its industry group as manufacturing and reports annual revenue in the $1 to $1,000,000 range.
The notice states that as of the filing, Glucose Health has sold $10,000 of securities in this offering, with an additional $20,000 remaining to be sold. The issuer reports paying $0 in finders' fees in connection with the offering. The first sale in this offering occurred on August 28, 2026.
Glucose Health, Inc., a Delaware corporation based in Bentonville, Arkansas, filed a notice of an exempt private securities offering relying on Rule 506(b) of Regulation D. The company reports revenue in the $1–$1,000,000 range.
The offering consists of investment units, each including one share of common stock and a warrant to purchase one share of common stock over five years at an exercise price of $0.60 per share. The notice shows $60,000 of securities sold, with an additional $60,000 remaining available in the offering, and discloses $0 in finders’ fees.